Trials / Completed
CompletedNCT01365962
Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma
A Study to Assess and Quantify Surface Insulin-like Growth Factor I Receptor (IGF-IR) in Rhabdomyosarcoma (RMS) Tumor Tissue
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with rhabdomyosarcoma.
Detailed description
OBJECTIVES: * To determine and quantify the degree of surface insulin-like growth factor I receptor (IGF-IR) expression in rhabdomyosarcoma (RMS) tumor tissue. * To assess the feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue. OUTLINE: Paraffin-embedded tumor tissue slides are analyzed for insulin-like growth factor I receptor (IGF-1R) expression by mass spectrometry and correlated with the results obtained by IHC assay.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | gene expression analysis | |
| OTHER | immunohistochemistry staining method | |
| OTHER | laboratory biomarker analysis | |
| OTHER | mass spectrometry |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2016-05-01
- First posted
- 2011-06-03
- Last updated
- 2016-05-19
Source: ClinicalTrials.gov record NCT01365962. Inclusion in this directory is not an endorsement.